Skip to main content

VYNE Therapeutics, Inc. (VYNE)

NASDAQ: VYNE · IEX Real-Time Price · USD
1.16 0.00 (0.34%)
Oct 22, 2021 9:35 AM EDT - Market open
Market Cap59.75M
Revenue (ttm)15.93M
Net Income (ttm)-88.37M
Shares Out51.41M
EPS (ttm)-1.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume118,024
Open1.15
Previous Close1.16
Day's Range1.14 - 1.18
52-Week Range1.09 - 11.20
Betan/a
AnalystsStrong Buy
Price Target5.00 (+329.6%)
Est. Earnings DateNov 4, 2021

About VYNE

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vul...

IndustryBiotechnology
IPO DateJan 25, 2018
Employees106
Stock ExchangeNASDAQ
Ticker SymbolVYNE
Full Company Profile

Financial Performance

In 2020, VYNE's revenue was $20.99 million, an increase of 4,638.83% compared to the previous year's $443,000. Losses were -$255.57 million, 168.5% more than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for VYNE stock is "Strong Buy." The 12-month stock price forecast is 5.00, which is an increase of 329.55% from the latest price.

Price Target
$5.00
(329.55% upside)
Analyst Consensus: Strong Buy

News

VYNE Therapeutics Announces Formation of Scientific Advisory Board

Renowned Experts to Support VYNE's Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases

1 day ago - GlobeNewsWire

VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Derm...

Important milestone achieved as part of the Company's new corporate strategy to develop treatments for immuno-inflammatory diseases

3 days ago - GlobeNewsWire

VYNE Therapeutics Announces its China Partner's Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients w...

BRIDGEWATER, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first patient has been enrolled in a Phase 3 study in China ...

2 weeks ago - GlobeNewsWire

VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference

BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the C...

1 month ago - GlobeNewsWire

VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference

BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the H...

1 month ago - GlobeNewsWire

3 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:NSPR
1 month ago - Benzinga

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0.00% and -31.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: VYNE Therapeutics Q2 Earnings

Shares of VYNE Therapeutics (NASDAQ:VYNE) fell 15.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 57.32% year over year to ($0.35), which were i...

2 months ago - Benzinga

VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Trea...

Company announced license agreement with In4Derm Limited for BETi platform earlier this morning

2 months ago - GlobeNewsWire

VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event

BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in a...

3 months ago - GlobeNewsWire

Why VYNE Therapeutics Stock Is Crashing Today

The drugmaker reported disappointing Q1 results.

5 months ago - The Motley Fool

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 7.50% and -18.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Conference call and live webcast today at 8:30 am Eastern Time Conference call and live webcast today at 8:30 am Eastern Time

5 months ago - GlobeNewsWire

VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and part...

7 months ago - GlobeNewsWire

VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 14.00% and -12.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update

Conference call and live webcast to discuss financial results and new FMX114 program in atopic dermatitis today, Thursday, March 4, 2021, at 8:30 am Eastern Time Conference call and live webcast to disc...

7 months ago - GlobeNewsWire

VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference

BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and part...

7 months ago - GlobeNewsWire

Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.

8 months ago - Benzinga

VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate ...

BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct offerin...

8 months ago - GlobeNewsWire

Can Vyne Therapeutics Stock Keep Soaring?

This biotech stock is jumping, but what should investors expect from its new skincare treatments?

8 months ago - The Motley Fool

VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq ...

BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”),  today announced that it has entered into definitive agreements with institutional a...

8 months ago - GlobeNewsWire

VYNE Stock: 13 Things to Know About Vyne Therapeutics as Shares Rocket Higher

Vyne Therapeutics (VYNE) stock is taking off on Wednesday as investors take an interest in the pharmaceutical company on recent news. The post VYNE Stock: 13 Things to Know About Vyne Therapeutics as Sh...

8 months ago - InvestorPlace

VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy...

BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel AMZEEQ® (m...

9 months ago - GlobeNewsWire